The VP of Clinical Development (U.S.-based) is accountable for the integrated clinical strategy, scientific leadership, and delivery of the company’s pipeline of therapies targeting immune-mediated diseases. This executive will lead development from candidate selection and IND/CTA-enabling activities through first-in-human (FIH), Phase 1, Phase 1b proof-of-mechanism (PoM), and Phase 2a proof-of-concept (PoC) studies, with scope to continue into later-stage development as programs mature.
The role requires deep expertise in early clinical development, strong medical and scientific judgment, and the ability to translate emerging data into clear decisions on dose, schedule, patient population, endpoints, biomarkers, and indication strategy.
The VP of Clinical Development will oversee Clinical Leads and Clinical Scientists, establish rigorous standards for clinical plans and study design, and work in close partnership with Clinical Operations to deliver high-quality global trials across multiple geographies and regulatory landscapes.
Working through a cross-functional Clinical Development Team, the VP of Clinical Development will provide unified clinical and scientific leadership, integrating regulatory, CMC, safety, translational, operational, and commercial considerations into a coherent development strategy and executable plan.
This plan will reflect the program vision, Target Product Profile, and value proposition; define clear clinical objectives and decision criteria; identify and manage critical risks; and enable timely, evidence-based decisions at key investment and governance milestones.
The VP of Clinical Development will lead by influence across functions and geographies and directly oversee Clinical Leads and Clinical Scientists. They will establish clear accountabilities, high standards for clinical and scientific work, transparent decision-making, and strong execution discipline.
The role will partner closely with Clinical Operations on feasibility, site and vendor strategy, enrollment, trial management, timelines, budgets, and data quality while retaining accountability for clinical strategy, protocol design, medical oversight, benefit-risk assessment, and interpretation of clinical data.
The VP of Clinical Development will collaborate with Research, Pre-clinical Development, Translational Science, Biomarkers, Clinical Pharmacology, Regulatory, CMC, Safety, DMPK, Project Management, Finance, and Business Development and will represent clinical development at senior governance forums and with external partners. This role reports to the Chief Medical Officer.
Ailux is an innovative biotechnology company harnessing AI to accelerate breakthrough biologic therapies in difficult immune-mediated diseases and improve the lives of patients with significant unmet medical need.
Built on intelligent design and guided by people who care about transforming healthcare, our technology is redefining what is possible in biologics development, from how we select targets to how we engineer the molecules.Ailux’s vision is to light the path to new cures and fundamentally change our approach to science and drug development to redefine current treatment paradigms.
We look to continue unlocking the potential of disease biology, integrate AI-enabled biologics development, and deliver effective clinical execution.Backed by an experienced leadership team, leading scientific advisors, a highly multidisciplinary organization, and strategic partnerships in biopharma, Ailux is approaching a key inflection point as its first wave of therapeutic programs advance toward clinical development.
This is an opportunity to play a vital role in leading programs from pre-clinical development into the clinic and through clinical proof-of-concept, shaping the pipeline and development culture of a rapidly growing biotechnology company.